LADY READING HOSPITAL
MEDICAL TEACHING INSTITUTION
PESHAWAR, PAKISTAN.

Medical Director ,
Medical Teaching Institution
Lady Reading Hospital
Peshawar, Pakistan.

Telephone: (091) 9211400
Facsmile: (091) 9211401
(091) 9210958
Email: medicaldirector@lrh.gov.pk

All Consultants
Lady Reading Hospital-MTI
Peshawar.

Subject: **ADVERSE DRUG REACTION REPORTING FORM**

In light of the Medical Staff By-Laws of the Affiliated Teaching Hospital Chapter-VII, Pharmacy & Therapeutics committee (P&T committee) section 1 sub-section 4.9, an Adverse Drug Reaction Reporting Form is hereby circulated for your information and submission to the P&T committee, and P&T committee will review adverse drug reactions in the hospital and recommend policies regarding the reporting of such reactions.

Encl: 01

Medical Director
Lady Reading Hospital-MTI,
Peshawar.

No. 3648-56 /LRH/PA
Dated: 13/11/2017

Copy forwarded for information and necessary action to the:-

1. Dean LRH-MTI
2. Hospital Director LRH-MTI
3. Chairperson of the Department LRH-MTI
4. Director Nursing LRH-MTI
5. Director Emergency Department LRH-MTI
6. Secretary BoG LRH-MTI
7. Inpatient Manager LRH-MTI
8. Pharmacy Manager LRH-MTI

Medical Director
Lady Reading Hospital-MTI,
Peshawar.

LADY READING HOSPITAL (MTI) PESHAWAR

DEPARTMENT OF PHARMACY SERVICES

Form No. _____

Date: _____

ADVERSE DRUG REACTION REPORTING FORM

For Voluntary reporting of Adverse Drug Reactions by healthcare professionals

IMPORTANT: DO NOT PLACE IT IN PATIENT'S RECORD

Advice about Reporting:

- Report adverse experiences with medications
- Report serious adverse reactions. A reaction is serious when the patient outcome is:
  - death
  - life-threatening (real risk of dying)
  - hospitalization (initial or prolonged)
  - required intervention to prevent permanent impairment or damage
  - disability (significant, persistent or permanent
  - congenital anomaly
- Report even if you're not certain that the product caused adverse drug reaction

Who can report?

- Any healthcare professional (Doctors including Dentists, Nurses and Pharmacists)

Where to report?

- Please return the completed form to Pharmacovigilance Centre (PVC), Department of Pharmacy, Lady Reading Hospital (MTI) Peshawar

What happens to the submitted information?

- Information provided in this form is handled in strict confidence. The causality assessment is carried out at the Pharmacovigilance centre (PVC) LRH-MTI Peshawar by using specific scale (recommended by WHO). The analysed forms are forwarded to Drug regulatory authority of Pakistan (DRAP) and further reported to WHO ADR monitoring centre.
- The reports are periodically reviewed by the Pharmacovigilance centre (PVC) LRH-MTI Peshawar. The information generated on the basis of these reports helps in continuous assessment of the benefit-risk ratio of medicines.
- The information is submitted to the Pharmacy & Therapeutic Committee (P&TC) LRH-MTI Peshawar. The Committee is entrusted with the responsibility to review the data and suggest any interventions that may be required.

Date:	**Reporting Person & Designation:**		
Patient Name:		**MR No.**	**Ward:**
Gender:	**Age (Years):**	**Weight (Kg):**	
Date of ADR:	**Suspected Drug(s):**		
Date of Recovery:			

DRUG TYPE

☐ Analgesic	☐ Bronchodilator	☐ IV Solution	☐ Other (specify)
☐ Antimicrobial	☐ Cardiovascular	☐ Laxative	
☐ Anticoagulant	☐ Contrast Media	☐ Narcotic	
☐ Anticonvulsant	☐ Corticosteroid	☐ Oxytocics	
☐ Antidepressant	☐ Diuretic	☐ Radionuclide	
☐ Antiemetic	☐ Immunization	☐ Sedative	
☐ Antihistamine	☐ Insulin	☐ Vasodilator	
☐ Antineoplastic	☐ Investigational	☐ Vasopressor	

Description of Reaction:

Reaction Management:

Reaction severity:

☐ Fatal ☐ Recovering ☐ Unknown
☐ Continuing ☐ Recovered
☐ Other (specify)

Seriousness of the Reaction:

☐ Death
☐ Life Threatening
☐ Prolonged Hospitalization
☐ Disability
☐ Congenital abnormality
☐ Required intervention to prevent permanent impairment/damage
☐ Other (specify)

Type of ADR:

☐ Augmented (A) ☐ Bizzare (B)
☐ False Alarm (F) ☐ Hypersensitivity

Confidentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction.

Reverse side to be completed by PVC-Pharmacist and to be returned to DPIC